Cidara Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.90
Dividend & YieldN/A$ (N/A)
Beta 1.43
Market capitalization 48.49M
Operating cash flow -22.38M
ESG Scores unknown

Company description

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -59k 9.02M 21.8M 6.23M
Total Cashflows From Investing Activities 14.3M -35k -186k -41k
Net Borrowings -2.96M -2.96M -2.96M -4.44M
Total Cash From Financing Activities 56.15M 14.27M 37.28M 44.6M
Change To Operating Activities -661k 238k 1.91M 2.39M
Issuance Of Stock 56.15M 14.3M 40.24M 49.04M
Net Income -59.02M -41.09M -72.11M -42.47M
Change In Cash 13.75M -14.29M -17.32M 19.32M
Effect Of Exchange Rate
Total Cash From Operating Activities -56.7M -28.53M -54.41M -25.23M
Depreciation 523k 328k 1.05M 189k
Change To Account Receivables 321k -10k -11.16M 5.82M
Other Cashflows From Financing Activities -31k -31k
Change To Netincome 2.17M 2.98M 4.11M 2.61M
Capital Expenditures -177k -35k -186k -41k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -59.02M -41.09M -72.11M -42.47M
Net Income -59.02M -41.09M -72.11M -42.47M
Selling General Administrative 14.14M 16.24M 15.9M 18.74M
Gross Profit -49.14M -25.49M -55.95M -23.52M
Ebit -63.28M -41.72M -71.85M -42.26M
Operating Income -63.28M -41.72M -71.85M -42.26M
Interest Expense -262k -262k -262k -212k
Income Tax Expense
Total Revenue 20.91M 12.07M 49.57M
Cost Of Revenue 49.14M 46.4M 68.02M 73.09M
Total Other Income ExpenseNet 4.27M 632k -262k -212k
Net Income From Continuing Ops -59.02M -41.09M -72.11M -42.47M
Net Income Applicable To Common Shares -69.34M -41.09M -74.87M -42.47M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 19.97M 31.14M 49.71M 53.75M
Total Stockholder Equity 59.14M 37.84M 10.71M 21.57M
Other Current Liabilities 411k 9.8M 13.87M 13.92M
Total Assets 79.11M 68.98M 60.42M 75.33M
Common Stock 3k 3k 4k 7k
Other Current Assets 10M 7.04M 2.59M
Retained Earnings -218.74M -259.83M -334.7M -377.17M
Treasury Stock
Cash 74.56M 50.27M 35.91M 59.68M
Total Current Liabilities 19.89M 30.2M 38.56M 34.02M
Other Stockholder Equity
Property, Plant, and Equipment 712k 2.06M 1.21M 2.54M
Total Current Assets 77.13M 65.81M 57.19M 71.7M
Net Tangible Assets 59.14M 37.84M 10.71M 21.57M
Net Receivables 2.57M 10k 11.18M 5.36M
Accounts Payable 2.85M 1.89M 4.57M 1.3M


Insider Transactions

Here are the insider transactions of stock shares related to Cidara Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
SHAH PREETAMSale at price 0.77 per share.D2022-09-19Chief Financial Officer15.64k
SHAH PREETAMD2022-09-15Chief Financial Officer50k
DARUWALA PAULSale at price 0.68 per share.D2022-09-12Chief Operating Officer16.2k
SANDISON TAYLORSale at price 0.68 per share.D2022-09-12Officer18.48k
TARI LESLIE PH.D.Sale at price 0.68 per share.D2022-09-12Officer18.16k
STEIN JEFFREYStock Award(Grant) at price 0.00 per share.D2022-03-31Chief Executive Officer573.74k
WARD SHANE MStock Award(Grant) at price 0.00 per share.D2022-03-31Officer104.03k
DARUWALA PAULStock Award(Grant) at price 0.00 per share.D2022-03-31Chief Operating Officer50k
SANDISON TAYLORStock Award(Grant) at price 0.00 per share.D2022-03-31Officer50k
JOHNSON BRADYStock Award(Grant) at price 0.00 per share.D2022-03-31Officer10k
SHAH PREETAMStock Award(Grant) at price 0.00 per share.D2022-03-31Chief Financial Officer117.25k
TARI LESLIE PH.D.Stock Award(Grant) at price 0.00 per share.D2022-03-31Officer52.5k
JOHNSON BRADYSale at price 0.81 per share.D2022-03-21Officer654
JOHNSON BRADYSale at price 0.71 per share.D2022-03-11Officer945
DARUWALA PAULSale at price 1.25 per share.D2022-01-05Chief Operating Officer5.13k
JOHNSON BRADYSale at price 1.25 per share.D2022-01-05Officer416
TARI LESLIE PH.D.Sale at price 1.25 per share.D2022-01-05Officer1.25k
STEIN JEFFREYD2021-12-29Chief Executive Officer20k
DARUWALA PAULD2021-12-29Chief Operating Officer9.9k
SANDISON TAYLORD2021-12-29Officer15.6k
JOHNSON BRADYD2021-12-29Officer262
TARI LESLIE PH.D.D2021-12-29Officer2.1k
STEIN JEFFREYPurchase at price 1.59 per share.D2021-11-12Chief Executive Officer50k
SHAH PREETAMPurchase at price 1.54 per share.D2021-11-12Chief Financial Officer20k
DARUWALA PAULStock Award(Grant) at price 0.00 per share.D2021-09-30Chief Operating Officer132k
SANDISON TAYLORStock Award(Grant) at price 0.00 per share.D2021-09-30Officer150.6k
JOHNSON BRADYStock Award(Grant) at price 0.00 per share.D2021-09-30Officer20.75k
JOHNSON BRADYStock Award(Grant) at price 0.00 per share.D2021-09-30Officer20.75k
TARI LESLIE PH.D.Stock Award(Grant) at price 0.00 per share.D2021-09-30Officer148k
FRANSON TIMOTHY RPurchase at price 2.12 per share.D2021-09-13Director7k
STEIN JEFFREYPurchase at price 1.72 - 1.79 per share.D2021-08-19Chief Executive Officer50k
DARUWALA PAULSale at price 2.06 - 2.66 per share.D2021-04-01Chief Operating Officer3.46k
ABDOLLAHIAN NEILSale at price 2.06 - 2.66 per share.D2021-04-01Officer4.34k
OIEN JESSICASale at price 2.06 - 2.66 per share.D2021-04-01General Counsel2k
STEIN JEFFREYStock Award(Grant) at price 0.00 per share.D2021-03-31Chief Executive Officer10k
DARUWALA PAULStock Award(Grant) at price 0.00 per share.D2021-03-31Chief Operating Officer1.4k
ABDOLLAHIAN NEILStock Award(Grant) at price 0.00 per share.D2021-03-31Officer3.5k
SANDISON TAYLORStock Award(Grant) at price 0.00 per share.D2021-03-31Officer700
OIEN JESSICAStock Award(Grant) at price 0.00 per share.D2021-03-31General Counsel2.8k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Cidara Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Cidara Therapeutics Inc

Here is the result of two systematic investment strategies applied to Cidara Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Cidara Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Cidara Therapeutics Inc:

Cidara Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -41.23% on the backtest period.

Performance at glance

Performance

-41.23 %

Latent gain

-722.24 $

Invested capital

1751.93 $

Annualized return

-10.06 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Cidara Therapeutics Inc

This is the result of two momentum investment strategies applied to Cidara Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Cidara Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Cidara Therapeutics Inc:

Cidara Therapeutics Inc momentum entries
  • The first momentum investment strategy would give -38.32% of return on Cidara Therapeutics Inc. That represents -1723.04$ of latent gain with 4496.93$ of employed capital.
  • The second momentum investment strategy would give -43.85% of return on Cidara Therapeutics Inc. That represents -1643.91$ of latent gain with 3749.19$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-38.32 %

Latent gain

-1723.04 $

Invested capital

4496.93 $

Annualized return

-13.37 %
Performance at glance (2Q Momentum)

Performance

-43.85 %

Latent gain

-1643.91 $

Invested capital

3749.19 $

Annualized return

-12.11 %

Momentum equity curve on Cidara Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Cidara Therapeutics Inc:

Cidara Therapeutics Inc momentum equity

Note: the dividends potentially given by Cidara Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Cidara Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Cidara Therapeutics Inc since the beginning:

Cidara Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Cidara Therapeutics Inc

Buy the dip entry openings on Cidara Therapeutics Inc

Cidara Therapeutics Inc

The performance achieved by the robo-advisor on Cidara Therapeutics Inc is -28.07%. That represents -210.8$ of latent gain with 750.89$ of employed capital. The following chart shows Cidara Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Cidara Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-28.07 %

Latent gain

-210.8 $

Invested capital

750.89 $

Annualized return

-13.37 %

Equity curve of the strategy applied to Cidara Therapeutics Inc

The following chart shows the result of the investment strategy applied to Cidara Therapeutics Inc:

Cidara Therapeutics Inc

Note: the dividends potentially given by Cidara Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Cidara Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Cidara Therapeutics Inc:

Cidara Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Cidara Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Cidara Therapeutics Inc.

Equity curve comparison on Cidara Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Cidara Therapeutics Inc investment strategy comparison

Employed capital comparison on Cidara Therapeutics Inc

Cidara Therapeutics Inc investment comparison

Performance comparison on Cidara Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -41.23% -722.24$ 1751.93$ -10.06%
Momentum 1 quarter -38.32% -1723.04$ 4496.93$ -9.93%
Momentum 2 quarters -43.85% -1643.91$ 3749.19$ -12.11%
Non-directional -28.07% -210.8$ 750.89$ -13.37%
Annualized return comparison

Automatic investment

-10.06 %

Momentum 1Q

-12.11 %

Momentum 2Q

-12.11 %

Non-directional

-13.37 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Cidara Therapeutics Inc:

Note: The algorithm computes the probability of correlation between Cidara Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Cidara Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Cidara Therapeutics Inc
Country United States
City San Diego
Address 6310 Nancy Ridge Drive
Phone 858 752 6170
Website www.cidara.com
FullTime employees 89
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker CDTX
Market www.nasdaq.com

Cidara Therapeutics Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown